Physician profile
Bryce Mays
NPI 1306854740
$11,911.86
in general payments reported to CMS, 2019-2025
38 companies · $2,704 in 2025
The $2,704 reported for 2025 was more than what 85% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $613 · 2020: $221 · 2021: $1,615 · 2022: $2,032 · 2023: $2,162 · 2024: $2,566 · 2025: $2,704.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,327 · Education: $104.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,327.00 |
| Education | $104.36 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,613.85 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $1,643.65 | 2019-2025 | Entyvio, Gattex, Eohilia |
| Janssen Biotech, INC. | $906.91 | 2019-2025 | Stelara, Tremfya, Simponi |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $696.98 | 2019-2025 | Xifaxan, Trulance, Plenvu |
| Celgene Corporation | $475.98 | 2021-2024 | Zeposia |
| Madrigal Pharmaceuticals | $457.84 | 2024-2025 | Rezdiffra, Resmetirom |
| Qol Medical, LLC | $416.02 | 2022-2025 | Sucraid, Sucraid |
| Lilly USA, LLC | $378.26 | 2023-2025 | Omvoh |
| Pfizer INC. | $338.88 | 2021-2025 | |
| Ironwood Pharmaceuticals, INC | $308.70 | 2021-2025 | Linzess |
| Regeneron Healthcare Solutions, INC. | $288.47 | 2022-2025 | Dupixent |
| Genzyme Corporation | $285.06 | 2022-2025 | |
| Ardelyx, INC. | $250.77 | 2022-2025 | Ibsrela |
| Gilead Sciences, INC. | $182.20 | 2023-2025 | |
| Braintree Laboratories, INC. | $178.06 | 2020-2024 | Suflave, Sutab |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Nestle Healthcare Nutrition INC. | $150.34 | 2021-2023 | |
| Celltrion USA INC. | $144.44 | 2023-2025 | Zymfentra, Vegzelma, Yuflyma |
| Intercept Pharmaceuticals, INC. | $115.81 | 2019-2025 | Ocaliva |
| Daiichi Sankyo INC. | $107.17 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $103.74 | 2019-2022 | |
| Evoke Pharma, INC. | $100.09 | 2022-2024 | Gimoti |
| Aimmune Therapeutics, INC. | $99.85 | 2024-2025 | Zenpep |
| Phathom Pharmaceuticals, INC. | $97.76 | 2024-2025 | Voquezna |
| Vivus LLC | $93.47 | 2022-2024 | Qsymia, Pancreaze |
| Ferring Pharmaceuticals INC. | $64.29 | 2022-2023 | Clenpiq |
| Shield Therapeutics INC | $55.08 | 2024 | |
| Novo Nordisk INC | $54.31 | 2025 | Wegovy |
| Medtronic, INC. | $52.88 | 2024 | Gi Genius |
| Ipsen Biopharmaceuticals, INC | $47.53 | 2024-2025 | Iqirvo |
| E.R. Squibb & Sons, L.L.C. | $39.69 | 2024 | Zeposia |
| Capsovision, INC. | $38.27 | 2023 | Capsocam Plus |
| Enterra Medical, INC. | $34.47 | 2024-2025 | |
| Covidien LP | $24.43 | 2019 | |
| Shire North American Group INC | $18.73 | 2019 | |
| Sandoz INC. | $17.55 | 2024 | Hyrimoz |
| Echosens North America, INC. | $16.65 | 2024 | Fibroscan |
| Allergan, INC. | $13.68 | 2020 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$43,328.38 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bryce Mays listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.